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Pseudomonas aeruginosa causes aggressive infection in patients with 
pre-existing disorders and recurrent pulmonary infections in cystic fibrosis 
patients. Pathogenesis of P. aeruginosa infections is multifactorial owing to 
numerous virulence factors. The focus of this thesis research was to investigate 
whether P. aeruginosa elastase (PE) causes remodeling of the cytoskeleton by 
increasing the phosphorylation of RhoA GTPase proteins. In addressing our 
hypothesis, we utilized Small GTPase Immuno-sorbent Activation assays (G-
LISA) and Enzyme linked Immuno-sorbent assay (ELISA) to quantitate changes 
in the total as well as phosphorylated RhoA protein in Calu3 cell lines. 
Fluorescence microscopy aided in understanding the changes in morphological  
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organization of F-actin. Changes in expression of TJ protein, ZO1, due to PE 
induced RhoA GTPase activity, was analyzed with SDS PAGE and Western Blot 
Analysis. Our data from G-LISA and ELISA assays indicate that PE increases the 
amount of active RhoA protein by 50.8% in comparison to PBS treated control 
cells. RhoA inhibitor reduced the PE-induced phosphorylation of RhoA proteins 
by 30.35 % in PE treated cells. Images from fluorescence microscopy revealed 
that increase in RhoA GTPase activity causes formation of specific morphological 
protrusions such as stress fibers, lamellipodium and filopodium. Presence of 
RhoA inhibitor reverses the changes induced by PE. Results from immuno-
sorbent assays and fluorescence microscopy indicate that inhibition of EGFR and 
MAPK significantly reduces the PE-induced GTPase activity of RhoA by 48.07 % 
and 42.2 % respectively. Data from G-LISA and ELISA assays correlate well with 
the morphology data obtained by fluorescence microscopy. Taken together, our 
data indicate that PE, at least in part, activates RhoA kinase via upstream EGFR 
and downstream MAPK signaling pathways, in vitro. The impact of these PE-
induced alterations in the anatomy and physiology of the tight junctional complex, 
and their impact on the homeostasis of the lungs, demands further investigation. 
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Chapter One 
Introduction 
Pseudomonas aeruginosa, a versatile Human Pathogen 
Pseudomonas aeruginosa, a non-fermentative, aerobic, virulent pathogen 
from the family Pseudomonadaceae, is responsible for causing a wide range of 
community and hospital-acquired infections in diverse clinical settings (1, 2). P. 
aeruginosa rarely causes infection in the normal host, but when a local or general 
immunodeficiency arises, it proves to be an efficient opportunistic pathogen.  P. 
aeruginosa-induced infections and pathologies often become more severe, 
damaging, and fatal in individuals with congenital immunodeficiency or with 
compromised immunity (2). 
P. aeruginosa is considered as one of the most common and lethal 
pathogens responsible for ventilator-associated pneumonia (VAP) in intensive 
care units (3, 9). Compared with community-acquired strains, clinical isolates 
of P. aeruginosa tend to be resistant to multiple classes of antibiotics, making its 
treatment extremely complicated with a mortality rate of 38% (4).  Ventilator-
associated pneumonia continues to be a common cause of morbidity and 
mortality in critically ill patients, despite extensive research in the areas of 
prevention and management (5, 6). One of the important components of treating 
patients with pneumonia is the initial assessment of the severity of disease. The 
Acute Physiology and Chronic Health Evaluation II (APACHE II) score was first 
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developed to predict patient mortality at the time of admission to a critical care 
unit (7, 9). The APACHE II score at the time of diagnosis and admission is 
considered the best scoring system to predict mortality in patients with VAP. P. 
aeruginosa ranks second in causing infection among all pathogens reported to 
the National Nosocomial Infection Surveillance System as well as rating high in 
the European Prevalence of Infections in Intensive Care Study (8). Other sites of 
nosocomial infections by this pathogen include the urinary tract, the bloodstream, 
surgical site infections, and post burn skin injuries. Localized proliferation of 
bacterium at the burnt site may lead to systemic sepsis, which is often associated 
with a high degree of mortality (11). Studies conducted on burned-mouse 
model have shown that P. aeruginosa quorum-sensing systems, las and rhl, play 
an important role in the horizontal spread of the pathogen within burned skin, 
facilitate bacterial dissemination and contribute to its overall virulence (12).  
The capacity of P. aeruginosa to produce such diverse, often 
overwhelming infections is due to the presence of an array of virulence factors 
(2). The low permeability of the cell wall of P. aeruginosa and its ability to efflux 
antimicrobial agents, make it intrinsically resistant to therapy.  Furthermore, 
selection of the most appropriate antibiotic is often complicated by the ability 
of the pathogen to develop resistance to multiple antibacterial agents during the 
course of treatment (14). The combination of these factors enables the bacterium 
to display high levels of virulence and resistance to infection control in acute and 
chronic settings (15). 
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Historical Relevance and Metabolic Adaptability 
The pathogen was first isolated in 1882 by a French chemist and 
bacteriologist Carle Gessard, through an experiment that identified this microbe 
due to its water soluble pigments that turned blue-green when exposed to ultra-
violet light (13). The Gram-negative aerobic rod shaped pathogen is capable of 
growing and surviving in almost any environment but it lives primarily in water, 
soil, and vegetation (2). The ubiquitous nature of the microorganism reflects its 
ability to survive with minimal nutrition requirements. The tremendous amount of 
metabolic versatility to adapt and colonize in diverse niches that are often 
inhospitable to most other organisms, is mainly due to the large and complex 
genome of the gammaproteobacteria (16, 17). Further, it also reflects the 
extraordinary physiological capabilities and broad metabolic capacity of the 
Pseudomonas aeruginosa that, particularly in low-nutrient conditions, provides 
distinct advantages for outgrowing competitors (18).  
The complete genome sequencing of wild type P. aeruginosa (PA01) has 
uncovered a great deal of useful information, concerning not only the various 
reasons for its pathogenicity but also revealing its potential for antibiotic 
resistance (19). Large number of genes for substrate uptake and catalysis have 
been identified which not only enable the bacterium to metabolize various 
compounds as nutrients but also facilitate high environmental adaptability (20). 
In addition to environmental habitats, P. aeruginosa strains are also 
frequently isolated from clinical sources.  It can colonize human body sites, with a 
preference for moist areas, such as the perineum, axilla, ear, nasal mucosa and 
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throat; it has also been isolated from the gastrointestinal tract. The organism 
colonizes the respiratory tract of mechanically ventilated patients, the 
gastrointestinal tract of patients receiving anticancer chemotherapy, and on the 
skin of burn patients (21, 22). The lung is a main target for colonization and 
infection by this bacterium, either in the context of a chronic, progressively 
deteriorating infection and inflammation in cystic fibrosis (CF) population, or in a 
more acute setting such as severe pneumonia in immunocompromised patients 
(23, 24). 
Infection Process 
Normally, in order to initiate the process of pathogenesis, P. aeruginosa 
must breach the normal cutaneous or mucosal barriers so as to substantially 
break the first-line of defenses of the human body. Such a break can result from 
either disruption of the junctional complex, interruption of the protective balance 
of normal mucosal flora by broad spectrum antibiotics, or alteration of the 
immunologic defense mechanisms such as chemotherapy-induced neutropenia 
or mucosal clearance defects in CF (2). Once P. aeruginosa colonizes the host 
tissues and systems such as the lungs, it promotes more pathologic changes 
including the obstruction of the host clearance mechanisms.  The process helps 
the bacterium to establish itself within the host and transform to resist host 
defenses and antibiotic therapy (2). During the initial colonization phase, P. 
aeruginosa successfully utilizes its repertoire of virulence factors to manipulate 
local physiology and overcome host defenses. These virulence determinants aid 
the infectious process to progress either to a chronic infection phase 
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characterized by low production of extracellular virulence factors, or to an acute 
infection characterized by high production of cell-to-cell signaling dependent 
virulence factors (32-34). Flagella, pili, and lipopolysaccharide are not only 
important for motility and adhesion but also serve as activators of Toll-like 
receptor 5 (TLR5), TLR2, and TLR4, which may lead to hyper inflammatory 
response (26, 27). P. aeruginosa also has the ability to halt epithelial cell protein 
expression and kill host cells by using the ADP-ribosylating protein ExoA. The 
type III secretion system (T3SS) effectors which includes both ExoS and ExoT, 
are known for their ADP-ribosyl transferase and GTPase activating events (28, 
29). They work in concert to inhibit actin polymerization, prevent blood cell 
migration and phagocytosis, and promote apoptosis (30). Along with other 
members of T3SS group, these virulence factors alter the epithelial layer by 
disrupting cell polarity, inducing damage, and preventing P. aeruginosa 
endocytosis and clearance from the respiratory tract (31). 
Virulence Factors  
Once the microbe invades the lung, it induces changes to reduce immune 
activation and obstruct clearance mechanisms for its persistence.  P. aeruginosa 
employs a suite of secreted enzymes and immunosuppressing factors to dampen 
host immunity (35, 36). These harmful factors include elastase (encoded by LasB 
gene), LasA protease, and alkaline metalloprotease (aprA), and are assumed to 
play a major role during acute P. aeruginosa infection (37). The role of alkaline 
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protease in tissue invasion and systemic infections is unclear; however, its role in 
corneal infections could be substantial (38, 39).  
Pseudomonas aeruginosa Elastase 
LasB elastase, the protease of interest in this project, is a 33 KDa zinc 
metalloprotease, also known as pseudolysin or P. aeruginosa elastase (PE). It 
acts on proteins such as human and bovine elastin and collagen Type III and IV 
(41-44). Also, research has shown that elastase producing P. aeruginosa strains 
were able to degrade proteins from human wound fluids and human skin biopsies 
ex vivo (45). Although not all clinical isolates of P. aeruginosa produce PE, for 
those that do, the protease is an important candidate in delineating the 
pathogenic status of the microorganism. LasB elastase is highly efficient, with a 
proteolytic activity on elastin approximately 10 times that of P. aeruginosa 
alkaline protease. Also, its activity toward casein is approximately four times 
greater than that of trypsin (40). The ability of P. aeruginosa to destroy elastin 
protein is a major virulence determinant during acute infection since elastin is the 
major component of connective tissues in human and plays a key role in the 
functions of the lungs and vasculature (46, 40).  
The concerted activity of two enzymes, LasB elastase and LasA elastase, 
is responsible for elastolytic activity which is believed to destroy elastin-
containing human lung tissue and cause the pulmonary hemorrhages 
characteristic of invasive P. aeruginosa infections (40). Apart from its elastolytic 
activity, PE degrades fibrin and collagen. Also, it can inactivate substances such 
as human immunoglobulins G and A, airway lysozyme, complement 
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components, and substances involved in protecting the respiratory tract against 
proteases such as α-1-proteinase inhibitor, surfactant proteins (SP) and bronchial 
mucus proteinase inhibitor (40). Thus, PE is known not only to cause destruction 
of the tissue components but also to interfere with host defense mechanisms by 
degrading a number of components of the innate and adaptive immune systems. 
For instance, PE hydrolyses both surfactant proteins A and D, which mediate a 
variety of events in lung innate immunity (47- 49). Incubation of either P. 
aeruginosa or purified Pseudomonas elastase with cell free bronchioalveolar 
lavage (BAL) resulted in the degradation of SP- A. The degradative enzyme from 
P. aeruginosa was identified as elastase by ion trap mass spectroscopy followed 
by its purification by anion exchange chromatography (50). We have also 
reported that incubation of PE with purified monoclonal antibodies (mAb) reduces 
the intensity of both 55 and 25 KDa bands in a SDS PAGE gel (71).   
Studies from our laboratory have confirmed the presence of PE in sputum 
samples of patients suffering from P. aeruginosa infection, using monoclonal 
antibody against PE (71). We have also reported that the purified Pseudomonas 
elastase increases paracellular permeability of epithelial linings in animal models 
of pulmonary edema (51, 52). We used in vitro model of epithelial paracellular 
permeability to understand the mechanism of action of PE in this phenomenon. 
Results of studies with primary cultures of alveolar type II pneumocytes indicated 
that PE enhances epithelial permeability by redistribution and/or degradation of 
tight junction proteins (53) (71). Similarly, in vivo studies done on guinea pigs 
showed an increase in lung epithelial permeability to macromolecules after 
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treatment with elastase (54). This increase in epithelial permeability was due to 
the disruption of the tight junctions between epithelial cells.  
Studies with P. aeruginosa mutants deficient in elastase secretion have 
indicated that PE plays a major role in the pathogenesis of Pseudomonas 
infection in animal models. In an air pouch model in rats, the number of 
leukocytes, volume of exudate and the concentration of interleukin-8 was 
analyzed post injection of P. aeruginosa elastase. The number of neutrophils and 
the volume of exudate in the pouch cavity treated with PE increased significantly, 
which indicates its proactive role in inflammatory response in Pseudomonas 
infection (70). Taken together, this evidence of elastase-generated virulence 
suggests that genetic manipulation of elastase production or neutralizing the 
protease at the site of infection could theoretically ameliorate pulmonary 
exacerbations caused by P. aeruginosa infection.  
Impact of PE on Epithelial Permeability 
Increased epithelial permeability is a well-accepted consequence of 
mucosal inflammation on the outer surfaces of various internal organs. The 
epithelium plays an important role in inflammation by serving as an interface 
between invading pathogens, allergens, and particles while communicating with 
underlying immune system of the host (58). According to the data from American 
Lung Association, lungs are responsible for the purification of 8,000 - 9,000 liters 
of breathed-in air in the course of a single day. This astonishing volume of 
purified air finally combines with 8,000 - 10,000 liters of blood pumped in by the 
heart through the pulmonary artery to fuel the cells of the body. The lungs also 
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relieve the blood of their burden of waste and return a refreshed, oxygen-rich 
stream of blood to the heart through the pulmonary vein. Under physiological 
conditions, polarized epithelia form a protective barrier that allows regulated 
paracellular fluxes of solutes and nutrients as well as facilitates antigen sampling 
and surveillance by the mucosal immune cells. However, during inflammation, 
this protective mechanism becomes compromised by various stimuli from either 
side of the epithelial barrier. Various invading microorganisms try to gain an 
access into the host tissue by increasing the epithelial permeability on the apical 
(luminal) side by releasing a variety of agents such as pore forming toxins, 
cytoskeleton-modifying proteins, and bacterial lipopolysaccharide (LPS). While, 
on the basal side of the epithelial layer, activated immune cells try also induce 
barrier disruption so as to facilitate their movement to sites of pathogen invasion. 
In this occasion, mucosal immune cells release variety of pro-inflammatory 
cytokines such as interferon (IFN), tumor necrosis factor (TNF), and interleukin 
(IL)1 or releases particular proteases and reactive oxygen species (ROS) in 
order to gain access to the epithelia (59, 60). Hence, increased permeability 
across the airway epithelial barrier is a major contributor to pathogenesis of 
respiratory infection and inflammation and understanding the underlying 
mechanisms that control the epithelial barrier disruption is important in identifying 
molecular targets that modulate mucosal inflammation (58).  
Tight Junctions Complex 
Properties of the epithelium are regulated by adhesive interactions that 
occur at the cell–cell and cell–matrix contacts by junctional proteins and focal 
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adhesion complexes. These intercellular junctional complex comprises of 
adhesive and scaffolding proteins such as tight junctions (TJs), adherens 
junctions (AJs), desmosomes, and gap junctions. These proteins are anchored 
into different cytoskeletal structures such as actin filaments, intermediate 
filaments, and microtubules (58, 63).  
 
                                                                                             (Image credits: Klaus Aktories & Joseph T. Barbieri, May 2005) 
Figure 1. Components of Tight Junction Complex 
 
Tight junctions are highly dynamic structures and are constantly being 
remodeled in response to their interactions with external stimuli, such as 
allergens, pathogens, and commensal bacteria (61, 62). Proteins constituting the 
TJ complex include the transmembrane proteins occludin, junctional adhesion 
molecule (JAM), claudin family members, and linker proteins that affiliate with the 
underlying actin cytoskeleton. TJ complex is usually associated to belt like 
structure of peri-junctional filamentous actin (F-actin) molecules that encircles the 
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cells. This structure cooperates with TJ proteins in the regulation of trans-
epithelial permeability or the ‘gate function’ of epithelial cells, and contributes to 
permeability regulation (64). These structures prevent the paracellular diffusion of 
macromolecules and microorganisms across the epithelial lining.  
Interaction of PE with Tight Junction Proteins 
Epithelial TJs are known to be influenced by a variety of endogenous and 
exogenous agents, including glucose, bacterial antigens, cytokines, and growth 
factors (65, 66, 67). During the process of inflammation, the apical junctions 
undergo the process of reorganization which in turn mediates epithelial barrier 
dysfunction. Such barrier dysfunction contributes to the pathogenesis of airway 
disorders such as asthma and acute lung failure. Defective epithelial barrier 
accelerates water influx into the lung which leads to pulmonary edema and 
further results in enhanced activation of the pulmonary and systemic immune 
responses by inhaled pathogens and allergens (68, 69). However, the 
mechanisms by which the external agents such as bacterial antigens, cytokines 
or growth factors signal to the TJs are not well understood. 
Interplay of Signal Transduction Pathways 
The transmission of extracellular signals to their intracellular targets is 
mediated by a network of interacting proteins that governs a large number of 
cellular processes. The modulation of TJ assembly and function could be via 
multiple signal transduction pathways including kinases, Ca2+, G proteins, 
calmodulin, adenosine 3’, 5’-cyclic monophosphate (cAMP), and phospholipase 
12 
 
C (72- 77). During bacterial infection, attachment of bacterium to host cells as 
well as extracellular virulence factors such as proteases, elicits responses in a 
variety of signal transduction pathways. These include the extracellular signal-
regulated kinase (ERK) arm of the mitogen-activated protein kinases (MAPK) 
and epidermal growth factor receptor (EGFR) which in turn triggers the host 
inflammatory response against the existing infection. (87). Activation of these 
intracellular tyrosine kinase residues can initiate stimulation of signaling 
pathways via several adaptor proteins and protein kinases such as the Ras 
oncogene signaling pathway. 
 
Figure 2. Schematic Representation of Cross Talk between EGFR-MAPK-Rho Signaling Pathways 
EGFR Signaling Pathway 
Epidermal growth factor receptor is a 170 kDa membrane glycoprotein, 
which belongs to the family of receptor tyrosine kinases that includes three other 
members, erbB2/HER-2, erbB3/HER-3, and erbB4/HER-4. The EGFR signaling 
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pathway is involved in a variety of physiological responses including proliferation, 
differentiation, motility, and survival (88). Receptor tyrosine kinases are 
composed of an extracellular ligand-binding domain, a short hydrophobic 
transmembrane region, and an intra-cytoplasmic tyrosine kinase domain. They 
share a similar structural homology with the other members of the family and are 
activated by multiple ligands including Epidermal growth factor (EGF), 
Transforming growth factor (TGF – α), heparin binding (HB)-EGF, amphiregulin, 
β-cellulin and epiregulin (89, 90). Activation of EGFR may involve two different 
pathways—ligand dependent and ligand independent EGFR tyrosine 
phosphorylation. Ligand independent EGFR phosphorylation is reported in 
response to cigarette smoke (91) and by activated neutrophils (92). Further 
analysis, however, revealed that the airway epithelial cells express EGFR pro-
ligands on their surface along with the EGF receptors. Specific stimuli such as 
cigarette smoke can induce shedding of EGFR pro-ligands from the epithelial cell 
surface, leading to ligand dependent activation of EGFR signaling cascade. 
Likewise, neutrophils present in the airways of patients with hypersecretory 
diseases such as COPD, acute severe asthma, and cystic fibrosis could promote 
ligand independent EGFR activation and mucin synthesis. This ligand 
independent activation of EGFR occurs via the release of oxygen free radicals 
which raises the possibility of interactions between these cells and epithelial cells 
resulting in ligand dependent activation of EGFR signaling cascades (91, 92).  
Previous studies from our lab indicate that PE induces activation of 
Protein Kinase C (PKC) signaling pathway through phosphorylation of Epidermal 
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Growth Factor Receptor (EGFR), which results in disruption of tight junction 
proteins, reorganization of the cytoskeleton, and destruction of epithelial barrier 
function (94).  
MAPK Signaling Pathway 
Mitogen-activated protein kinase (MAPK) pathways are evolutionarily 
conserved kinase modules that link extracellular signals to the machinery that 
controls fundamental cellular processes such as growth, proliferation, 
differentiation, migration and apoptosis. Currently, six distinct groups of MAPKs 
have been characterized in mammals which includes extracellular signal-
regulated kinase (ERK) 1/2, ERK3/ 4, ERK5, ERK7/8, c- Jun N-terminal kinase 
(JNK)1/2/3 and the p38 isoforms. Historically, ERK signaling was synonymous 
with cell proliferation but it is now clear that dysregulation of this pathway is 
linked to many other aspects of the tumor phenotype. ERK signaling is activated 
by numerous extracellular signals as well as auto-phosphorylation of MEK and 
Raf (93). Activation of the MAP kinases-extracellular signal regulated kinases 
(MAPK/ERK) 1/2 has been associated not only with cell survival, proliferation, 
growth and differentiation but also with TJ protein disruption and cytoskeletal 
rearrangements. Previous studies from our lab have indicated that activation of 
the extracellular signal-regulated kinases (ERK) 1/2 arm of the mitogen-activated 
protein kinase (MAPK) pathway is involved in PE-induced TJ disruption (Azghani, 
unpublished data). Further, it was demonstrated that PE induces phosphorylation 
of ERK proteins within 5 minutes of apical exposure, preceded by a loss of 
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localization of TJ proteins occludin and ZO-1 along with the reorganization of the 
actin cytoskeleton (Azghani, unpublished data). 
Recent advances in understanding the signaling pathways important for 
cytoskeletal rearrangements during cell migration have indicated that these 
pathways might have their relevance in the biogenesis and/or the maintenance of 
Tight Junctions. For example, the small GTP binding protein Rho regulates actin 
filament organization, and is important for the organization and permeability of 
the TJ in polarized epithelial cells (78). Also, most of the actin filaments are 
positioned under the apical junctional complex where myosin II and several actin 
binding proteins have been identified including α-actinin, vinculin, and radixin.  
This indicates the significance of actin binding proteins in the assembly and 
regulation of TJs and the associated reorganization of the architecture of the 
actin cytoskeleton (79).  
RhoA Signaling Pathway 
Rho family of small guanosine triphosphate (GTP)–binding proteins, one 
of the five distinct families of the Ras superfamily, has been shown to be 
important in the regulation of epithelial TJ structure, function, and assembly (80).  
The discovery of Rho protein was serendipitous in 1985 as a Ras-related protein 
(Ras homology) in Aplysia, and subsequently 18 genes encoding Rho-like 
proteins were identified in the human genome, with Rho, Rac and Cdc42 being 
the far best characterized (81, 82). The members of Rho family are small (21-25 
kDa) molecules that act as molecular switches to regulate signal transduction 
pathways, by interconverting between inactive GDP-bound and active GTP-
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bound conformational states. Studies have revealed the importance of Rho 
GTPases in regulation of various processes in reference to actin cytoskeleton 
including migration, phagocytosis, endocytosis, morphogenesis and cytokinesis. 
The first direct evidence that Rho and Rac regulate the assembly and 
organization of filamentous actin (F-actin) in response to extracellular cues was 
provided in 1992 (83, 84). In that study, Rho was shown to promote the assembly 
of contractile actomyosin filaments in response to lysophosphatidic acid (LPA) in 
a fibroblast cell line. In addition, Rac was shown to promote the assembly of a 
peripheral actin meshwork, leading to formation of lamellipodia and membrane 
ruffles in response to platelet-derived growth factor (PDGF) or insulin (83, 84).  
 
(Image credits: Laurent Blanchoin, Rajaa Boujemaa-Paterski, Cécile Sykes, and Julie Plastino, 2014) 
Figure 3. Diverse Morphologies of Actin Cytoskeleton 
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Interaction of RhoA GTPases with Actin Cytoskeleton 
Inactivation of Rho GTPases with Clostridium botulinum C3 transferase 
toxin or Clostridium difficile toxins A and B is associated with reorganization of F-
actin in the perijunctional F-actin ring. These effects on the actin cytoskeleton 
were also shown to be accompanied by changes in TJ structure and function 
such as disruption of intercellular junctions. This results in the redistribution of 
VE-cadherin from the cell- cell contacts and formation of gaps in the monolayer 
(78). Additional studies using transfected epithelial cell lines expressing mutants 
of Rho GTPases have documented that Rho proteins play an important role in 
the regulation of TJ structure and function (85, 86). However, molecular 
mechanisms by which Rho proteins influence TJs of epithelial cells are not yet 
clear. 
Hypothesis 
In this study, we provide evidence in support of the hypothesis that P. 
aeruginosa elastase mediates activation of RhoA GTPases.  We also sought to 
determine the cell signaling pathways that PE exploits in this process.  We 
addressed our hypothesis by investigating that whether PE alters F-actin 
structure and organization by interconverting between the inactive GDP bound to 
active GTP bound conformational state of RhoA proteins. PE-induced RhoA 
activation was assessed by using Small GTPases linked Immuno-sorbent assay 
(G- LISA). Total RhoA was quantitated by   Enzyme-linked immuno-
sorbent assay (ELISA). We confirmed our immunochemical data by fluorescence 
microscopy. We found that PE-induced phosphorylation of RhoA proteins, a 
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downstream mediator of Rho-ROCK (Rho-associated kinase) signaling pathway, 
causes restructuring of the actin cytoskeleton. Further, we explored the 
molecular mechanisms that PE exploits to phosphorylate RhoA intermediate in 
Rho-ROCK signaling cascade. Our data revealed that that PE activates RhoA 
through EGFR and MAPK signaling pathways. These findings were further 
supported by the morphological analysis of Calu-3 monolayer treated with 
specific inhibitors of EGFR and MAPK.  
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Chapter Two 
Material and Methods 
I. Cell Culture: We used a human bronchial adenocarcinoma epithelial cell line 
(Calu-3) from American Type Culture Collection (ATCC, Manassas, Virginia), as 
an in vitro model to understand the role of Pseudomonas Elastase (PE) induced 
RhoA GTPases activity in cytoskeleton reorganization, Tight Junction (TJ) 
proteins disruptions and increased epithelial permeability leading to pulmonary 
edema . The cells were cultured and maintained in Dulbecco's Modified Eagle's 
Medium (Gibco, Life Technologies, Grand Island, NY) at 37°C in humidified 
atmosphere of 5% CO2 / air. The medium was supplemented with 10% Fetal 
Bovine Serum (FBS; Atlanta Biologicals, Lawrenceville, GA), 1% L-glutamine 
(Cellgro, Herndon, VA) and cocktail of antibiotics containing Penicillin (100 U/ml), 
streptomycin (0.1mg/ml), and Amphotericin B (25 µg/ml), all from Cellgro, 
Herndon, VA.  Cells were maintained in   tissue culture flasks (Corning, Corning, 
NY) and were discarded at passage numbers 20. The medium for the flasks was 
changed every other day to avoid nutrient depletion. We used trypsin/EDTA 
(0.25%, Gibco, Life Technologies, Grand Island, NY) to transfer the cells from 
flasks to the appropriate cell culture ware according to the experimental design:  
a. Biochemical and Immunological assays:  We utilized different assays 
for understanding the PE induced RhoA GTPases activity in Calu-3 cell lines. For 
experimental purposes, cells were plated at high density (250,000 cells/well) in 6-
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well tissue culture plates (Corning, Costar). The cells density/well was kept high 
so they reach confluency within short interval of time. 
b. Fluorescence Microscopy: For analyzing the morphological changes in 
actin cytoskeleton, Calu-3 cells, at 8x 105 cells/well, were cultured on 8 - well 
chamber slides (Lab-Tek, Rochester, NY). Calu-3 cells were grown to 80 % 
confluence in complete medium containing 10% FBS. Prior to treatments, the 
serum content in the medium was dropped gradually from 10% to 1% within a 
time interval of 12 hours followed by a complete serum starvation for 6 hours.  
II. Specific Antibodies & Reagents: We used purified P. aeruginosa elastase 
(Elastin Product Co, Owensville, MO) as the primary bacterial toxin in this 
project. The purity and enzymatic activity of P. aeruginosa elastase (PE) was 
confirmed by using an elastin-fluorescein assay as directed by the manufacturer. 
One unit of purified P. aeruginosa elastase will hydrolyze 1 µgm insoluble elastin 
per hour at 37°C. Elastase was applied apically on Calu-3 monolayers at a 
concentration of 3 U/ml.  
Specific inhibitors of EGFR and MAPK pathways were utilized to 
understand the significance of various signal transduction pathway involved in 
PE-induced RhoA activation. These reagents include “EGFR inhibitor AG1478” 
(Calbiochem, La Jolla, CA, USA), “MEK 1&2 inhibitor U0126” (Calbiochem, La 
Jolla, CA, USA) and Rho inhibitor I (CTO4) (Cytoskeleton, Inc., Denver, CO). The 
product CT04, with molecular weight of 24 kDa, is based on the exoenzyme C3 
Transferase from Clostridium botulinum which has been covalently attached to a 
proprietary cell penetrating moiety.  
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III. Treatment Protocols: Cells were pre-treated for 15 minutes with 1μM of either 
“EGFR inhibitor AG1478” or “MEK 1&2 inhibitor U0126” or with 500ng/ml of Rho 
Inhibitor for 2 hours prior to PE exposure.  As a positive control, we treated the 
cells with Human thrombin (Sigma, St. Louis, MO) or Human recombinant 
Epidermal Growth Factor (EGF) (R&D Systems, Inc., MN) for 10 minutes. All 
inhibitors were diluted in serum free DMEM. Solutions prepared for different 
treatments were then utilized in various biochemical, morphological and 
functional assays.   
IV. Sample Preparation 
Rho Activation Assay: The Small GTPases linked Immuno Assay (G-LISA) 
(Cytoskeleton, Inc., Denver, Colorado, USA) was utilized to detect the active 
form of Rho proteins in cell lysates. Calu-3 cells were grown to 80% confluence 
in 6 well tissue culture plates in complete media (DMEM) containing 10% FBS. 
The serum content in the medium was dropped gradually from 10% to 1% within 
a time interval of 12 hours followed by a complete serum starvation for 6 hours. 
Cells were then treated with the following mediators in the absence of serum.  
Thrombin (1.0 U/ml), PE (2.0 - 3.0 U/ml), EGFR inhibitor (10 µM/ml), Erk1/2 
inhibitor (10 µM/ml) and Rho Inhibitor I (0.5 µg/ml). Upon stimulation for 5 min at 
37oC, we rapidly processed the cell lysates as follows.   
The culture plate was placed on ice to aspirate off the culture medium and 
cells were washed with ice cold PBS. The cells were lysed by using 70 µl of ice 
cold Cell Lysis Buffer while keeping the culture plate on ice. The cell lysates were 
then harvested by using a cell scraper (Sarstedt AG & Co., Nümbrecht, 
22 
 
Germany) and transferred to pre-labeled micro-centrifuge tubes on ice.  The 
lysates were clarified by centrifugation at 10,000 x g at 4 0C for 1 minute. We 
used 10 µl of cell lysates for protein quantitation process while rest of the lysates 
were saved in aliquots at -70 0C. If the sample variation amongst the cell lysates 
was more than 10%, following formula was used for the normalization of the 
protein samples by adding ice cold Cell Lysis Buffer to more concentrated 
samples:  
A – B/B x volume of A = V (Volume of Lysis Buffer to be added) 
 [where A is the higher concentration lysates (mg/ml) and B is the concentration 
of the most dilute sample (mg/ml)]. 
Once the cell lysate concentration was normalized, lysis buffer was diluted 
with ice cold binding buffer to prepare buffer blank while positive control for the 
assay was prepared by diluting GTP- RhoA protein with lysis buffer and ice cold 
binding buffer in a pre-labeled micro-centrifuge tube and utilized within 15 
minutes as it will be denatured otherwise. Required number of 96-well strips were 
then placed on strip holder on ice and the powder in the wells was dissolved by 
adding 100 µl ice cold sterile water. Immediately, frozen lysates were thawed out 
by moving them in room temperature water bath and then subsequently 
transferred to ice. In order to ensure avoidance of high background noise, we 
applied a series of 5-7 vigorous pats of plate prior to the removal of solution from 
the wells. This was followed by the pipetting of normalized cell lysates and the 
ice cold binding buffer along with the positive control and buffer blank for the 
group into the respective wells. Immediately the plate was placed on a vortex 
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mixer (Fisher Scientific, Waltham, MA) at 40C for 30 minutes at 400 rpm. The 
solution was then removed and the wells were washed twice with wash buffer by 
using multi-channel pipette. The antigen presenting buffer was then added into 
each well, followed by a 2 minute incubation at room temperature. This step is 
followed by removing the solution and immediate washing of wells at room 
temperature thrice with wash buffer as outlined above. All the wells were 
incubated with primary antibody diluted in antibody dilution buffer while keeping 
the plate on shaker at 400 rpm for 45 minutes at room temperature. Post 
incubation with primary antibody, the solutions were flicked out and the wells 
were washed with wash buffer thrice at room temperature. Secondary antibody 
dilution was prepared with antibody dilution buffer prior to addition into the wells 
and the plate was incubated for 45 minutes at orbital shaker at 400 rpm in room 
temperature. This was followed by removing solutions from the wells and 
washing thrice with wash buffer. Finally, horseradish peroxidase enzyme (HRP) 
detection reagent solution was added into each well followed by incubation of the 
plate at 37°C for 15 minutes. At the end of the reaction, HRP stop buffer was 
added and the absorbance signal was measured at OD490 nm using AD340 
spectrophotometer and analysis software (Beckman Coulter, Brea, CA).  
V. Enzyme-linked Immuno-sorbent Assay (ELISA) for Total RhoA measurement: 
The Total RhoA ELISA Assay Kit (Cytoskeleton, Inc., Denver, CO) was used for 
the quantitative measurement of RhoA in cell extracts. The kit is a highly 
selective sandwich ELISA format where each well is pre-coated with anti-Rho IgY 
antibody with a high affinity for Rho isotypes. The presence of RhoA in sample 
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lysates will allow its binding to the bottom of well. This step is followed by 
treatment with monoclonal antibody and its subsequent detection by secondary 
antibody- HRP conjugate and the substrate. Before the cell lysate are thawed 
out, four different concentrations of positive control was prepared for the assay in 
a pre-labeled micro-centrifuge tube. The thawed cell lysates were then mixed 
with sample dilution buffer into separated micro-centrifuge tubes. Required 
numbers of wells were placed on strip holder plate on ice. The powder in the 
wells were dissolved by adding 100 µl M Q water at room temperature. Once the 
powder in wells was dissolved, the solution from the wells were completely 
removed. This requires series of 5-7 vigorous flicks of the plate onto paper towels 
so that the high background noise in the wells could be avoided. This was 
followed by the pipetting of equalized cell lysates into the respective wells for a 
period of 2 hour incubation at room temperature. The solution was then removed 
and the wells were washed twice with wash buffer by using multi-channel pipette. 
The antigen presenting buffer was then added into each well for 2 minute at room 
temperature. This step is followed by flicking out the solution and immediate 
washing of wells at room temperature thrice with wash buffer. This is followed by 
the incubation of wells with primary antibody for 60 minutes at room temperature. 
The solutions were removed and the wells were washed with wash buffer thrice 
at room temperature. Incubation with secondary antibody was performed for 
another 60 minutes in room temperature. This is followed by the flicking out of 
solutions from the wells and washing thrice with wash buffer. Finally, HRP 
detection reagent solutions were added into each well followed by its incubation 
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at 37 for 15 minutes. At the end of the reaction, HRP stop buffer was added and 
the absorbance signal was measured at OD490 as indicated above.   
VI. Biochemical assay: The cell lysates for biochemical assays were prepared 
according to the aforementioned protocol for G- LISA.   
a. Gel Electrophoresis: Protein samples were processed with 4X laemmlli 
sample buffer (BioRad, Hercules, CA) complemented with β- mercaptoethanol. 
Samples were heated at 95°C for ten minutes followed by a quick cycle of 
centrifugation to remove cell particles. The proteins were then separated in a 
12% Sodium dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
by using a Mini-Protean electrophoresis apparatus (BioRad, Hercules, CA). Each 
lane was loaded with 20 μg of protein or 5 μl of BioRad molecular weight 
makers161-0318. The proteins were electrophoresed by using NuPAGE® MOPS 
SDS Running Buffer (20X) (Life Technologies, NY) at 40V for 10 minutes 
followed by a run at 100V for 1 hour. We used Acqua stain protein gel stain 
(Bulldog Bio, Inc., NH) to stain the gels for 15 minutes. The unstained gels were 
equilibrated in TBST (Tris Buffer Saline (TBS), 0.1% Tween 20) buffer before 
using them for Western Blot Transfer. 
  b. Western Blot Analysis: Separated proteins were then transferred to a 
0.45 μm nitrocellulose membrane in a BioRad Trans Blot Turbo system. The 
membranes were then blocked for 2 hours with 5% bovine serum albumin in 
TBST (Tris Buffer Saline (TBS), 0.1% Tween 20) at room temperature. The 
appropriate primary antibody dilution of either occludin (1:250) (Cell Signaling 
Technology, Inc. Danvers, MA) or ZO-1 (1:250) (Invitrogen, Carlsbad, CA) was 
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added for overnight at 4°C. Secondary antibody GAR (Goat anti Rabbit) -HRP 
(BioRad, Hercules, CA) was added for 2 hours at room temperature. An 
amplification step was performed using a Blot Amplification module (BioRad, 
Hercules, CA). After amplification, colorimetric detection was performed using 
Opti-4CN Substrate Kit (BioRad, Hercules, CA) for 30 minutes. Immunoblots 
were documented using UVP GelDoc-IT imaging System (UVP, Upland, CA) and 
quantified with ImageJ software (NIH, USA). 
VII. Immuno-staining: Confluent monolayers of Calu-3 cells were seeded on 8 – 
well tissue culture treated chamber slides (Lab-Tek, Rochester, NY) as 
mentioned earlier. Morphological changes induced by Pseudomonas Elastase in 
the absence or presence of various inhibitors across the confluent cell 
monolayers were then analyzed after the cells were stained for F-actin. The cells 
were fixed with 3.7 % paraformaldehyde in PBS for 10 minutes followed by cell 
permeabilization step with 0.5% Triton-X 100 in PBS for 5 minutes at room 
temperature. Finally, the treated cells were incubated with Acti-Stain 555 
Fluorescent Phalloidin (Cytoskeleton, Inc., Denver, CO) in PBS for 30 minutes in 
the dark at room temperature for F- actin visualization. The cells were then 
washed thrice with PBS. This is followed by counterstaining of cells with 100 nM 
DAPI (4’, 6’–di-amidino-2-phenylindole, Invitrogen, Camarillo, CA). The 
monolayers were examined under Zeiss LSM 5 Pascal Laser scanning Confocal 
Microscope equipped with an Axiocam HRc Color Digital Camera (One Zeiss 
Drive, Thornwood, NY). Photomicrography was performed under 63X with oil and 
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images were overlaid and pseudo-colored (green –actin) for ease of visualization 
in LSM software by Zeiss.  
Changes in the formation of stress fibers, cell cortex and protrusions such 
as lamellipodium and filopodium helped to determine and compare the 
differences in F- Actin organization pattern. Differences in the localization of tight 
junction proteins were visually observed and documented as well.  
VIII. Statistical Analysis: Statistical analysis of the differences between the 
means was performed with GraphPad Prism 6 (GraphPad Software, San Diego, 
CA). Results from spectrophotometric analysis of immunological assays such as 
G-LISA and ELISA and densitometric analysis from Western Blot are evaluated 
by using ANOVA followed by hoc pairwise comparisons and Dunnett’s t-test. 
Results are presented as means ± standard deviation and considered significant 
when p-value < 0.05.  
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Chapter Three 
Results 
 
Activation of RhoA GTPases by Pseudomonas aeruginosa Elastase (PE) 
 
We sought to investigate whether PE alters F-actin structure and 
organization through activation of RhoA intermediate in Rho-ROCK pathway.  
We compared the RhoA GTPases activity in cells treated with PE alone to that of 
the PBS-treated control monolayers. We observed that PE increases the 
phosphorylation of RhoA proteins significantly over the PBS treated control 
monolayers in vitro (1.787 ± 0.15 vs 1.188 ± 0.17, p<0.05, n =3). The RhoA 
GTPase activity in PE treated Calu 3 cells was 50.8% higher than the PBS 
treated control cells. Further, we analyzed whether inhibitor of RhoA was able to 
slow down the phosphorylation activity of RhoA proteins induced by PE.  Calu-3 
cells were pre-treated with RhoA Inhibitor for 120 minutes and later with PE for 5 
minutes. Cell lysates at the end of 5 minutes of PE exposure were normalized 
and analyzed through G-LISA activation Assay in colorimetric format. 
Spectrophotometric analysis of cell lysates showed that the specific RhoA 
inhibitor reduced the kinase activity in PE-treated cells by 30.35%.In the 
experimental setup, a purified phosphorylated RhoA protein was utilized as a 
positive control as shown in Figure 1.  These changes in the phosphorylation 
state of RhoA Proteins was found to be correlated with the morphological 
changes in the F-actin molecules as shown in Figure 4. 
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Figure 1 b depicts the amount of phosphorylated RhoA kinase.  The 
concentration of phosphorylated RhoA proteins was observed to be significantly 
higher in PE treated monolayers than the PBS treated control cells (1.080 ± 0.13 
vs 0.706 ± 0.04, p< 0.05, n=3).  The amount of PE-induced phosphorylated RhoA 
protein was as high as the positive control, whereas, Calu-3 monolayers 
pretreated with RhoA inhibitor reduced the amount of activated kinase 
significantly (0.49 ± 0.03.vs 1.080 ± 0.13, p<0.005,n=3).  
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Figure 4a. Pseudomonas aeruginosa Elastase induces RhoA GTPase phosphorylation. Confluent 
monolayers of Calu- 3 were pre- treated with 500ng/ml of RhoA inhibitor for 120 minutes followed 
by stimulation with 3U/ml of PE for 5 minutes. PE induced RhoA GTPase phosphorylation was 
measured by G-LISA Small G- Protein Activation Assay. Data is expressed as means ± standard 
deviation of triplicate assays. * indicate significant increase (p=0.003) in RhoA GTPase 
phosphorylation in PE treated cells in comparison to PBS-treated control cells. # indicates decrease 
in RhoA GTPase phosphorylation in RhoA inhibitor treated cells in comparison to PE treated Calu-3 
monolayer.  
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Figure 4b. Concentration of Phosphorylated RhoA GTPase measured by G-LISA: Confluent 
monolayers of Calu- 3 were pre- treated with 500ng/ml of RhoA inhibitor for 120 minutes followed 
by stimulation with 3U/ml of PE for 5 minutes. Data is expressed as means ± standard deviation of 
triplicate assays. # indicate significant increase (<0.001) in RhoA GTPase phosphorylation in PE 
treated cells in comparison to PBS-treated control cells.* indicates decrease in RhoA GTPase 
phosphorylation in PE + RhoA inhibitor treated cells in comparison to PE- treated cells. 
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Inhibition of EGFR/ MAPK signal transduction pathway attenuates PE-induced 
RhoA GTPase activity 
  
In an effort to understand the mechanism by which PE increases RhoA 
GTPase activity in Calu-3 cells, we investigated the effect of PE on RhoA 
GTPase activation in the presence of specific inhibitors for Epidermal Growth 
Factor Receptor (EGFR) and Mitogen Activated Protein Kinase (MAPK) 
pathways. We observed that Calu-3 monolayers treated with P. aeruginosa 
elastase significantly increased the amount of active GTP bound RhoA in cell 
lysates in comparison to the PBS treated control cells (1.839 ± 0.06 VS 1.21 ± 
0.12, p< 0.05, n=3).  In this series of experiments, Calu-3 monolayers were pre-
treated with AG1478, a specific EGFR tyrosine kinase inhibitor or U0126, a 
highly selective inhibitor of MAPK/ERK kinase (ERKi) for 15 minutes. Cells were 
also pretreated with RhoA inhibitor CTO4 for 120 minutes prior to PE treatment. 
The monolayers were then exposed to 3 U/ml PE for 5 minutes and the cell 
lysate were analyzed for RhoA activity by G-ELISA.  Similar to our findings 
shown in Figures 1a and b, PE increase RhoA activity by 51% over the PBS-
treated control cells. However, we observed a pronounced  loss in  RhoA 
GTPase activity  in monolayers pretreated with EGFRi in comparison to cells 
treated with PE alone (0.9773 ± 0.03 vs 1.839 ± 0.06, p<0.05, n=3). Similarly, 
cells pre- treated with UO126 showed reduced kinase activity analogous to the 
EGFRi treatment, wherein the phosphorylation of RhoA proteins was significantly 
reduced (1.027 ± 0.05 vs 1.839 ± 0.06, p<0.05, n=3). Analysis of cell lysates 
treated with CTO4 showed similar effect as EGFRi and ERKi. Taken together, 
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our data indicate that PE, at least in part, activates RhoA kinase via upstream 
EGFR signaling and downstream MAPK pathways.   
 
  
Figure 5. Signal transduction pathways involved in PE induced RhoA GTPase. Confluent 
monolayers of Calu- 3 were pre- treated with 500ng/ml of RhoA inhibitor, 1µM EGFR inhibitor or 
1µM of MEK inhibitor for 120 minutes and 15 minutes respectively, followed by stimulation with 
3U/ml of PE for 5 minutes. PE induced RhoA GTPase phosphorylation measured by G-LISA Small 
G- Protein Activation Assay was found to be attenuated in presence of inhibitors. Data is expressed 
as means ± standard deviation of triplicate assays. # indicate significant increase (p= 0.05) in RhoA 
GTPase phosphorylation in PE treated cells in comparison to PBS-treated control cells. * indicates 
decrease in RhoA GTPase phosphorylation in various inhibitor treated cells in comparison to PE - 
treated cells. 
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Quantitative Measurement of Total RhoA Proteins by ELISA Assay 
Enzyme-linked Immunosorbent Assay (ELISA) was used for the 
quantitative measurement of Total RhoA protein in cell extracts treated with PE in 
the presence and absence of RhoA inhibitor. Confluent monolayers of Calu-3 
were pre- treated with 500ng/ml of RhoA inhibitor followed by stimulation with 3 
U/ml of PE for 5 minutes. The amount of total RhoA protein in cell lysates was 
quantified by spectrophotometric analysis. The amount of Total RhoA protein 
was observed to be significantly higher in PE treated cells in comparison to PBS 
treated cells (1.138 ± 0.05, vs 0.87 ± 0.08, p <0.05, n= 3).  Calu-3 monolayer 
treated with RhoA inhibitor reduced the amount of total RhoA protein to the level 
of the PBS treated control cells.  (Figure 3a).  
 We analyzed the concentration of Total RhoA protein in cell lysates in the 
presence of inhibitors specific to EGFR and MAPK pathways to investigate the 
role of potential upstream and downstream signaling pathways.  Confluent 
monolayers of Calu-3 were pre- treated with 500ng/ml of RhoA inhibitor, 1 µM 
EGFR inhibitor AG1478 or 1 µM of MEK 1&2 inhibitor U0126  for 120 minutes 
and 15 minutes respectively, followed by stimulation with 3 U/ml of PE for 5 
minutes. The amount of total RhoA GTP proteins was reduced by 12.12% in cells 
pretreated with EGFRi in comparison to cells treated with PE alone. Cells pre- 
treated with “MEK 1&2 inhibitor UO126” showed results analogous to the EGFRi 
treatment, wherein the total RhoA protein was reduced by 15.4%.  Analysis of 
cell lysates treated with RhoA inhibitor CTO4, showed similar effect in 
comparison to EGFRi and ERKi treated cells as shown in Figure 3b. The degree 
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of increase in total RhoA protein is considerably less than that of active RhoA 
described above. 
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Figure 6a. Concentration of Total RhoA protein in PE induced infection as measured by ELISA 
Assay. Confluent monolayers of Calu- 3 were pre- treated with 500ng/ml of RhoA inhibitor, was 
stimulated with 3U/ml of PE for 5 minutes. ELISA measured the total amount of RhoA protein was 
expressed in cell lysates treated with both PE and PE with RhoA inhibitor. Data is expressed as 
means ± standard deviation of triplicate assays. # indicate significant increase (p< 0.05) in RhoA 
GTPase phosphorylation in PE treated cells in comparison to PBS-treated control cells. * indicates 
decrease in RhoA GTPase phosphorylation in RhoA inhibitor treated cells in comparison to PE- 
treated  cells. 
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Figure 6b. Concentration of Total RhoA protein in presence of various inhibitors as measured by 
ELISA Assay: Confluent monolayers of Calu- 3 were pre- treated with 500 ng/ml of RhoA inhibitor, 
1 µM EGFR inhibitor or 1 µM of MEK inhibitor for 120 minutes and 15 minutes respectively, 
followed by stimulation with 3 U/ml of PE for 5 minutes. Total amount of PE- induced RhoA protein 
was measured by ELISA Assay. Data is expressed as means ± standard deviation of triplicate 
assays. # indicate significant increase (p<0.05) in total RhoA in cell lysates treated with PE in 
comparison to PBS-treated control cells. * indicates decrease in the total concentration of RhoA 
protein in various inhibitor treated cells in comparison to PE- treated  cells  
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Pseudomonas aeruginosa Elastase alters Actin Cytoskeleton Architecture by 
RhoA Activation 
 
We sought to determine whether the phosphorylation of RhoA proteins by 
P. aeruginosa Elastase induces remodeling of the actin cytoskeleton. We 
compared F-actin organization in Calu-3 control monolayer to PE treated cells in 
the presence and absence of specific inhibitors of signaling pathways Rho-
ROCK, EGFR, and MAPK. Rhodamine staining of filamentous – actin (F-Actin) 
followed by its visualization and analysis on LSM 5 Pascal laser scanning 
confocal microscope revealed that the cells treated with 3 U/ml of PE for 5 min 
extensively altered the cellular architecture by formation of stress fibers (Figure 
4). The PBS- treated cells displayed regular cytoskeletal distribution in cell cortex 
and peripheries (Figure 4). Pre- treatment with RhoA inhibitor restored the 
organization of cell cortex and reduced the formation of stress fibers in 
comparison to PE treated cells (Figure 4) whereas, pre- treatment with MEK and 
EGFR inhibitor for 15 minutes reduced the effect of PE considerably. The cell 
peripheries became visible and the amount of stress fibers formation was 
reduced within the area. Monolayer treated with MEK and EGFR inhibitor 
induced the formation of other morphological protrusions such as lamellipodium 
and filopodium  
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Figure 7. Actin Cytoskeleton architecture is affected by PE induced RhoA GTPase activity. Confluent Calu-
3 monolayers were stained for F-actin where narrow arrows indicate formation of stress fibers, bold arrows 
indicate cell cortex and peripheries and arrow with double heads indicate formation of lamellipodium and 
triangle indicates filopodium. (A) In PBS treated cells, regular distribution of cell cortex and peripheries 
along with few stress fibers and lamellipodium was observed. (B) PE treatment (3 U/ml, 5 min) altered the 
cellular architecture and induced formation of extensive stress fibers and lamellipodium. (C) RhoA inhibitor 
pre-treated cells restored the organization of cell cortex and regular lamellipodium. (D) EGF treated cells 
(positive control) caused similar reorganization of actin cytoskeleton by formation of stress fibers. (E) and 
(F) MEK inhibitor and EGFR inhibitor pre-treated cells reinstated the effect of PE by formation of cell 
cortex, lamellipodium and filopodium. Images are representative of triplicate assays and scale bar is 20 
µm. 
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Inhibition of RhoA/EGFR/ MAPK pathway affects the expression of ZO-1 tight 
junctional protein 
 
We next investigated whether PE-induced RhoA activation and 
cytoskeletal alterations affect expression of TJ protein Zonula Occludens (ZO-1). 
We observed that exposure to PE for 5 minutes does not reduce the ZO1 
expression from the cell lysates. Cell lysates were prepared by the similar 
protocol followed in G-LISA/ELISA protocols. Western blotting analysis of SDS-
PAGE separated proteins was performed using monoclonal mouse anti-ZO1 
antibodies. Density of the bands were measured for comparative analysis. PE at 
3 U/ml for 5 minutes was unable to induce significant changes in the 
concentration of ZO-1 protein in the monolayers. The data revealed high ZO-1 
expression in cytoplasmic fraction of the cell lysates in response to PE while the 
cells treated with inhibitors of RhoA, EGFR and MAPK showed a decrease in the 
ZO-1 expression. The results obtained from the densitomertric analysis of the 
bands were not statistically significant. Beta actin bands indicate equal loading of 
the samples.   
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Figure 8. Expression of ZO-1 is affected by attenuation of RhoA/EGFR and MAPK 
pathway. Confluent monolayers of Calu- 3 were pre- treated with 500ng/ml of RhoA 
inhibitor, 1µM EGFR inhibitor or 1µM of MEK inhibitor for 120 minutes and 15 minutes 
respectively, followed by stimulation with 3U/ml of PE for 5 minutes. Proteins separated via 
SDS PAGE electrophoresis was transferred to Western Blot membrane. PE induces 
increase in RhoA GTP proteins in comparison to cells treated with inhibitors. The data from 
densitometry Analysis is observed to be insignificant (>0.05) 
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Chapter Four 
Discussion 
Pathogenic bacteria use toxins and proteases to cause tissue damage 
and they escape from the host defenses through proteolysis of extracellular as 
well as cell-associated immune effector cells and molecules (95-96). The 
molecular determinants of the host play an important role in pathogen-host 
interactions as well. Pulmonary epithelia presents a hostile environment for the 
antigens and foreign particles. Therefore, human pathogens must possess 
multiple virulence factors to manipulate host anatomy and physiology including 
the Immune system. Multiple secreted and cell associated virulence determinants 
contribute to P. aeruginosa pathogenicity. Proteases secreted by P. aeruginosa 
are exemplary in this respect, and even though not all clinical isolates of P. 
aeruginosa produce elastases (40, 45), for those that do, this particular protease 
proves to be an important candidate for providing the microorganism with 
immuno evasive capacity. 
In this study, we set forth the hypothesis that PE induces remodeling of 
actin cytoskeleton via activation of RhoA-ROCK signaling pathway. The PE 
mediated reorganization of the microfilament may depend on multiple signaling 
pathways including upstream EGFR and downstream MAPK. We addressed this 
hypothesis using G-LISA and ELISA immunoassays. We utilized specific 
inhibitors of target signaling pathways to investigate the mechanism of action of 
PE-induced alteration of cytoskeleton.  Further, the morphological changes 
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induced by PE were evaluated in the absence and presence of specific inhibitors 
of EGFR and MAPK cascades using fluorescence microscopy.  
 The data from G-LISA assay show that PE induces phosphorylation of 
RhoA protein, the first intermediate kinase in Rho-ROCK signaling pathway. The 
members of Rho family of GTPases act as molecular switches that are known to 
regulate signal transduction pathways by interconverting between inactive GDP-
bound and active GTP-bound conformational states (83). Membrane bound 
signaling pathways bring Rho proteins to the membrane through the action of 
specific membrane bound regulatory proteins, guanine nucleotide exchange 
factors (GEFs). GEF activates RhoA proteins at the membrane by releasing them 
from GDP bound state for GTP. Membrane bound activated Rho –GTP then 
binds to effector proteins such as Rho associated Kinase (ROCK) to induce 
changes in the underlying cytoskeleton. Rho GTPases, in general, mediates 
various processes in reference to actin cytoskeleton which includes migration, 
phagocytosis, endocytosis, morphogenesis and cytokinesis. During the process 
of inflammation via various agents such as cytokines and bacterial products 
including proteases, rapid disassembly of adherence junctions occurs in 
conjunction with the remodeling of the F-actin cytoskeleton. The close 
relationship between the F-actin rearrangement and the epithelial TJ complex 
reorganization indicates that the Rho proteins might affect the epithelial barrier 
function through cytoskeletal modification.  
Published reports indicate that Rho proteins regulate the assembly and 
organization of filamentous actin (F-actin) in response to lysophosphatidic acid 
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(LPA) in a fibroblast cell line (83). Rac was shown to promote the assembly of a 
peripheral actin meshwork, leading to formation of lamellipodia and membrane 
ruffles in response to platelet-derived growth factor (PDGF) or insulin (83, 84). 
Our study indicated that the mechanism of PE-induced pulmonary injury and 
identify signaling pathways involved. The main objective of this thesis research 
was to investigate the molecular mechanisms of PE-induced alteration in Calu-3 
pulmonary cells cytoskeleton. Herein, we report that the PE increased RhoA 
GTPase activity significantly within 5 minutes of exposure (Figure 1a). 
Pretreating the monolayer with RhoA inhibitor significantly reduces the 
phosphorylation of RhoA Proteins in the presence of P. aeruginosa Elastase. The 
RhoA inhibitor utilized for the study was a highly purified C3 Transferase which is 
covalently linked to a proprietary cell penetrating moiety via a disulfide bond. 
These findings therefore suggests that the RhoA GTPase activity is significantly 
enhanced in presence of PE which may further aid the pathogen in the 
establishment of epithelial injury in Calu-3 cells.  
Enzyme-linked Immuno-sorbent Assay (ELISA) was used for the 
quantitative measurement of total RhoA protein in cell extracts. This assay was 
utilized to determine the total amount of RhoA protein which included both the 
phosphorylated as well as non-phosphorylated kinase. The results from the 
ELISA assay indicate that PE increases concentration of total RhoA protein as 
well.   
We confirmed our immunoassay data with fluorescence microscopy of the 
cells labeled with Rhodamine.  Fluoresce images indicated that PE causes 
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extensive restructuring of the underlying actin cytoskeleton. These changes 
included formation of stress fibers and other distinct morphological structures 
such as lamellipodium and filopodium. Several studies indicate the importance of 
RhoA GTPase pathway in reorganization of the F- actin in response to 
extracellular cues. A number of in vitro studies have investigated the effects of 
microbial toxins and inflammatory mediators on the organization of the epithelial 
F-actin cytoskeleton. These studies have demonstrated that inflammatory stimuli 
alter structure of peri-junctional F-actin in conjunction with Adherens Junction 
Complex (AJC) disassembly (100). Moreover, incubation of colonic and renal 
epithelial cells with interferon (IFN) (97) or TNF (98) causes reorganization of the 
peri-junctional F-actin belt into different contractile structures such as apical 
rings, vacuoles, or stress fiber-like cables. Similar contractile F-actin structures 
were observed when pulmonary epithelial cells were subjected to hypoxia or 
treated with transforming growth factor (TGF) (99). We observed that PE induces 
significant morphological changes in the Calu-3 monolayer by formation of stress 
fibers, lamellipodium and filopodium. In response to protease such as PE, actin 
filaments rapidly cross-link at the leading edge of the membrane to form 
protrusions such as lamellipodium.  In some cases, PE causes formation of 
stress fibers where the contractile fibers in the cell cortex squeezes the cell body 
forward and the meshwork of actin filaments in the leading edge of cell causes 
the forward movement of cell. The presence of significant number of stress fibers 
and other pronounced morphological protrusions in Calu-3 cells within 5 minute 
of PE exposure suggest that PE causes modification of the actin cytoskeleton via 
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activation of RhoA GTPase proteins (Figure 5). This finding is supported by the 
data from the small GTPase activation assays for RhoA GTPase proteins where 
significant expression of RhoA GTPase proteins was observed in such a short 
time, a common phenomenon in cell signal transduction process. 
As for the molecular mechanism of PE-induced cytoskeleton remodeling in 
Calu3 lung epithelia, we used specific inhibitors to target signaling pathways of 
EGFR and MAPK.  
We explored the molecular mechanisms that PE exploits to restructure the 
underlying actin cytoskeleton. Interestingly, inhibition of RhoA GTPase activity by 
inhibitors of either RhoA, EGFR, or MEK attenuates reorganization of the 
cytoskeletal architecture induced by PE. Previous studies from our lab indicate 
that PE induces activation of Protein Kinase C (PKC) signaling pathway through 
phosphorylation of EGFR, which results in disruption of tight junction proteins, 
reorganization of the cytoskeleton, and destruction of epithelial barrier function 
(94). This further suggests that PE might exploit more than one downstream 
signal transduction cascades in the reorganization of actin cytoskeleton. Further, 
a cross-talk between the RhoA , EGFR, and MAPK signal transduction pathways 
might be involved  in the pathogenesis of PE induced F- actin assembly and 
reorganization. 
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Properties of the epithelium are regulated by adhesive interactions that 
occur at the cell–cell and cell–matrix contacts by junctional proteins and focal 
adhesion molecules (101). Epithelial tight junctional complexes are characterized 
by their dynamic nature and the ability of being constantly remodeled in response 
to their interactions with external stimuli, such as allergens, pathogens, and 
commensal bacteria (61, 62). Alteration of this process, however, may result in 
TJ disassembly and a subsequent increase in cellular permeability. Recent 
studies have revealed the importance of RhoA GTP binding proteins in the 
biogenesis, maintenance and regulation of epithelial Tight Junction structure, 
function and assembly (78). However, the molecular mechanisms by which Rho 
proteins influence TJs of epithelial cells are not yet clear.  
Due to the close association between cytoskeleton and zonula occluden 
proteins, we investigated the role of PE-induced F-actin alterations on ZO-1 
protein expression and organization. We observed a general trend where, ZO-1 
protein expression in the cytoplasmic fraction was up-regulated in cell lysates 
treated with PE. The results obtained from the study did not demonstrate 
statistically significant changes. On the other hand, the presence of RhoA, EGFR 
and MEK inhibitors reduced the expression of ZO-1 protein in the first 5 minutes 
of PE apical exposure, as detected by western blot analysis.  We speculate that 
PE-induced activation of Rho GTPase proteins will affect epithelial barrier 
function through F-actin-related dislocation of ZO-1 from inner leaflet of the 
membrane to cytosol, a phenomenon that needs further exploration.  
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In conclusion, the results from this study indicate that Pseudomonas 
Elastase is capable of quickly activating RhoA GTPase via EGFR/MAPK 
pathways. Activation of Rho-ROCK pathway resulted in distinct morphological 
changes in F- actin architecture. The impact of this PE-induced alterations in the 
anatomy and physiology of tight junctional complex and its implication on the 
homeostasis of the lungs demands further investigation.  
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